Fri, Jul 25, 2014, 5:45 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Exelixis, Inc. Message Board

common_10cents 4 posts  |  Last Activity: Jul 8, 2014 10:27 PM Member since: Jan 4, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • as much as I hate to say it, when Mama is elected as our next President (and I assure you, she will win), stem cell stocks will flourish, big time! google Hillary and Stem Cells to view her position(s)...

    Sentiment: Hold

  • Reply to

    ATHX

    by pcuauhtemoc Jul 2, 2014 1:56 PM
    common_10cents common_10cents Jul 3, 2014 1:18 PM Flag

    A year or so ago, when asked about the future of stem cells, a strategic relationship director at Roche stated "everyone knows stem cells work, we're all waiting on the proof of concept studies - then we look for partnerships"....

  • common_10cents common_10cents Jul 3, 2014 10:33 AM Flag

    nice find. healing well post is another plus that bolsters the argument...

    I sell equipment to the folks that are doing research in the Stem Cell arena...they see the legitimacy. The advancements of (instrument) technology has enabled the pace of discovery (to be) 100 fold faster than 5 years ago; a subtle indicator of how quickly things are moving and that we are indeed, on the cusp.

  • google it...from New Scientist -

    People who received the world's first stem cell treatment for strokes have shown measurable reductions in disability and handicap a year after the injection into their damaged brains.

    Some can move limbs and manage everyday tasks that were impossible before they received an injection of neural progenitor stem cells, which were clones of cells originally taken from the cortex of a donated fetus.

    Apart from physical rehabilitation, there are few treatments for people left severely disabled by a stroke. Demand for more options is high, with 800,000 new cases each year in the US and 150,000 in the UK.

    "We're encouraged, and it's a nice progressive piece of news," says Michael Hunt, the chief executive officer of ReNeuron, the company in Guildford, UK, that developed the treatment. "We must be circumspect, but we are seeing what seems to be a general trend towards improvement in a disparate group of patients," he says.

    ReNeuron presented its latest results on the first 11 patients on 7 May in Nice, France, at the 23rd European Stroke Conference. They build on interim findings released last year.

EXEL
4.19-0.02(-0.48%)Jul 25 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.